A randomised controlled trial of intramyometrial oxytocin versus placebo as adjuncts to paracervical tourniquet in reducing blood loss during abdominal myomectomy

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

PACTR

Registry ID

PACTR202606720982011

Enrollment

280

Registered

2026-06-09

Start date

2026-02-02

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine fibroid

Interventions

Normal saline

Intramyometrial oxytocin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Diagnosis of uterine fibroids between 12 weeks and 30 weeks uterine sizes with a treatment plan for open abdominal myomectomy. Consenting patients

Exclusion criteria

Exclusion criteria: Known allergy to oxytocin and or previous adverse reaction(s) to oxytocin. Previous uterine surgery (myomectomy or Caesarean section). Known history of bleeding or clotting disorders. Patients on anticoagulants Haematocrit at 24 hours before surgery less than 30%. Previous uterine artery embolisation Previous use of gonadotropin- releasing hormone drug Jehovah Witnesses Patient’s refusal to participate in the study

Design outcomes

Primary

Measure	Time frame
Estimated intraoperative blood loss(millilitres)	—

Secondary

Measure	Time frame
Volume of blood transfused ( millitres) Change in packed cell volume(%) Side effects of oxytocin and placebo	—

Countries

Nigeria

Contacts

Public ContactMutiu Popoola

Consultant

popoolamutiu@gmail.com+2348066487137

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 10, 2026